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Abstract
Background: Natural history of primary biliary cirrhosis (PBC) is partially characterized in patients from the Mediterranean area
whose genetic background differs from that of Northern Europeans.
Objectives: We aimed to describe genetic susceptibility and clinical course of PBC in patients from Southern Italy.
Methods: Socio-demographic, clinical, biochemical and histological data at diagnosis as well as disease progression of 81 PBC con-
secutive patients were collected. All subjects were treated with Ursodeoxycholic acid at a dose of 15 mg/kg. HLA class II DRB1 alleles
were compared with those of 237 healthy control subjects. IL28B genotyping for IL28B rs12979860 C/T and rs80899917 G/T was per-
formed in a sub-group of patients.
Results: HLA-DRB1*07 (RR 5.3, P = 0.0008) and HLA-DRB1*08 (RR n.c. P = 0.0005) were significantly associated with the risk of PBC de-
velopment. Patients younger than 45 years had significantly higher alanine aminotransferase (P = 0.038) and alkaline phosphatase
levels (P = 0.047) than older cases. In comparison to non-CC rs12979860, patients with CC rs12979860 genotype showed an early his-
tological stage at onset (93.8% vs. 62.5%, P = 0.03). After a mean follow-up of 61 months, three patients died, one underwent liver
transplantation and sixteen (21.9%) had progression of the disease. At multivariate analysis, extrahepatic autoimmune disease (P =
0.04), pruritus (P = 0.008) and advanced histological stage (P < 0.0001) were independent risk factors for disease progression.
Conclusions: HLA-DRB1*07 and HLA-DRB1*08 alleles increase susceptibility to disease development. At onset, higher biochemical
activity was observed in younger patients, whereas rs12979860 CC genotype was associated with milder histological stage. Pruritus
and coexistence of extrahepatic autoimmune diseases were significantly associated with poorer prognosis.
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1. Background
Primary biliary cirrhosis (PBC) is a chronic cholestatic
autoimmune disease of unknown etiology that mainly tar-
gets cholangiocytes of interlobular bile ducts. It primar-
ily affects middle-aged women between the 5th and 6th
decade, with a female/male ratio of 10:1. The disease has
a slowly progressive course towards liver cirrhosis and
death with a strong individual variability of progression
rate. Currently, Ursodeoxycholic Acid (UDCA) is the only
drug specifically approved for the treatment of PBC (1).
Incidence of PBC is extremely variable, ranging from
0.7 per million to a maximum average of 49 per million
per year registered in Olmsted County, Minnesota (2). It
seems that prevalence and incidence of the disease is in-
creasing worldwide (3); this finding may be influenced by
an increased exposure to potential environmental triggers
or simply may be the result of a greater awareness of the
disease amongst physicians.
Even if the pathogenesis of the disease is still unclear,
it most likely results from a combination of genetic factors
and superimposed environmental triggers. The role of ge-
netic susceptibility is clear, as demonstrated by a 100-fold
higher risk of developing PBC in relatives and a 60% con-
cordance in monozygotic twins (4). Furthermore, a weak
susceptibility conferred by the DRB1*08 allele of the hu-
man leukocyte antigen (HLA) class II (5) and a protective
effect related to HLA DRB1*11 and DRB1*13 alleles have been
demonstrated in Italian and UK series (6, 7). More inter-
estingly, several components of an innate and adaptive im-
mune system have been shown to play a critical role in es-
tablishing a greater susceptibility to PBC, as clearly stated
by recent genome-wide association studies (GWAS) (8-12).
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Finally, a possible role of environmental triggers, such as
infectious agents, xenobiotics, reproductive hormone re-
placement therapy and cigarette smoking, has been advo-
cated, even if none of them has been definitively confirmed
(13-16).
Few population-based studies on epidemiology and
natural history of PBC have been conducted (17-21) and only
three (19-21) of them are in the past decade. In particular,
very few data exists on patients from the Mediterranean
area, whose genetic background and risk factors might dif-
fer from those of other populations of Northern Europe
and of Northern Italians (22).
In addition, there is no current data regarding a po-
tential association between the clinical course of PBC and
Interleukin (IL) 28B polymorphisms, whose rs12979860 CC
and rs8099917 TT genotypes strongly predict the sponta-
neous clearance of HCV infection and the sustained vi-
rologic response after antiviral therapy in patients with
chronic hepatitis C (23). Recently, our group has shown
a link between IL28B polymorphisms and severity of liver
disease in terms of both necroinflammatory activity and fi-
brosis in 160 patients suffering from non-alcoholic steato-
hepatitis (24). Although IL-28 is involved in immune de-
fense against viruses, it also plays a role in the adaptive
immune response, as its inclusion as an immunoadjuvant
during animals vaccination leads to augmented antigen-
specific Interferon Gamma (IFN-γ) release as well as an in-
creased cytotoxic potential in CD8+ T cells (25, 26).
2. Objectives
The aim of our study was to perform a cohort study to
describe genetic susceptibility and clinical course of PBC in
patients from Southern Italy. In addition, a subgroup anal-
ysis was carried out to assess the potential impact of IL28B
polymorphisms on the clinical expression of the disease.
3. Methods
3.1. Patients
This study was carried out on a sample of 81 consecu-
tive patients with PBC who were recruited at the gastroen-
terology and liver unit of Azienda Ospedaliera Policlinico
Universitario P. Giaccone of Palermo, Italy, from January
2001. Patients were included if they had a diagnosis of
PBC according to the American association for the study
of liver diseases (AASLD) guidelines (27), based on the pres-
ence of two out of three of the following criterias: (i) bio-
chemical evidence of cholestasis with elevation of alkaline
phosphatase activity; (ii) presence of anti-mithocondrial
autoantibodies (AMA) positivity with titer ≥ 1: 40; (iii)
histopathologic evidence of non-suppurative cholangitis
and destruction of small or medium-sized bile ducts.
Histological staging, available in 77 patients, was per-
formed according to Scheuer’s classification. Four patients
did not undergo liver biopsy because of advanced age.
The exclusion criterias were: (i) other causes of liver
disease or mixed etiologies, including overlap syndromes;
(ii) significant alcohol consumption, i.e. superior to 21 alco-
hol units per week in men and 7 - 14 alcohol units per week
in women (28), evaluated by interview (iii) HIV infection;
(iiii) geographical origin outside Mediterranean area (Fig-
ure 1).
Clinical and biochemical data was collected at the time
of the diagnosis and then every 6 months. The diagnosis
of extrahepatic autoimmune diseases was made on clin-
ical grounds following the diagnostic criteria commonly
used for each single rheumatologic condition, without any
grading/staging of the diseases. The presence of symp-
toms was assessed by interview. Patients with PBC-related
symptoms (itching, jaundice, fatigue) or with symptoms
ascribable to the autoimmune diseases associated with
PBC (xerostomia, xerophthalmia, joint pain) were defined
as symptomatic.
3.2. HLA Class II Genotyping
In a subgroup of PBC patients (n = 31), normally dis-
tributed for age, clinical presentation and histological
stage, DNA typing of HLA class II alleles of Major Histo-
compatibility Complex (MHC) was performed using the
MicroSSP DNA Typing trays by One Lambda (Canoga Park
CA, USA). Firstly, the DNA was extracted from 200 µL of
whole peripheral blood using the PureLink Genomic DNA
Kit (Invitrogen by Life technologies) according to the man-
ufacturer’s instructions. Secondly, DNA genotyping was
performed by a single polymerase chain reaction (PCR) se-
quence specific primer (SSP) in accordance with the pro-
tocol, which was provided by the manufacturers (One
Lambda, Canoga Park CA, USA). This method permits to dis-
criminate each allelic difference overtaking the problem
of possible ambiguous results linked to the cross-reagent
group, typical of serological typing. The PCR products were
separated on 2% agarose gel containing ethidium bromide
and visualized under ultraviolet light. HLA class II DRB1
alleles were also genotyped in a control group of healthy
subjects (n = 237) with the same method (MicroSSP DNA
typing trays by one lambda). These patients belonged to
the same population in terms of geographic distribution.
Moreover, the selected subjects grandparents were all born
in the Western part of Sicily. For this control group we used
the entire reference of the healthy blood donor popula-
tion.
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Figure 1. Flowchart of Enrollment
3.3. IL28B Genotyping
IL28B genotyping for rs12979860 and rs8099917 poly-
morphisms was carried out in a subgroup of patients (n =
32). DNA was purified from whole-blood patient samples
using the QIAmp DNA blood mini kit (Qiagen, Mainz, Ger-
many). DNA samples were quantified using the Quant-iT™
PicoGreen® dsDNA Assay Kit (Invitrogen, Pasley, UK) and
stored at 20°C. Genotyping for rs12979860 and rs8099917
was carried out using the TaqMan SNP genotyping allelic
discrimination method (Applied Biosystems, Foster City,
CA, USA). A commercial genotyping assay was available for
the rs8099917 (cat. C_11710096_10), while a custom assay
was created by AB for rs12979860.
3.4. Follow-Up and Treatment
A liver ultrasound was performed at the diagnosis and
then annually in pre-cirrhotic patients as well as every 6
months in cirrhotic patients. Later, an esophagogastro-
duodenoscopy was performed every 1 - 3 years. Further-
more, patients with medium to large esophageal varices
underwent primary prophylaxis of variceal bleeding ac-
cording to the BAVENO V guidelines (29).
All patients were treated with UDCA (average dose: 15
mg/kg/day). In absence of the biochemical response to
UDCA, as defined by the Barcelona or Paris criteria (30), ei-
ther budesonide, fenofibrate or colchicine were added to
UDCA.
Out of 81 patients, eight were lost during the follow-
up. The other 73 patients were followed up for a period
of at least one year. Disease progression was defined as
the development of one or more of the following compli-
cations: esophageal varices, ascites, sonographic signs of
portal hypertension, portosystemic encephalopathy, hep-
atocellular carcinoma (HCC), orthotopic liver transplanta-
tion (OLT) and death.
3.5. Ethical Approval
This study was performed in accordance with the prin-
ciples of the declaration of Helsinki and its appendices as
well as with the local and national laws. Approval was ob-
tained from the hospital’s internal review board and the
ethical committee, as well as written informed consent
from all patients.
3.6. Statistical Analysis
Continuous variables were summarized as mean ±
standard deviation and categorical variables as frequency
and percentage. Mann-Whitney orχ2 tests were used as ap-
propriate to compare continuous or categorical variables.
All patients were divided into groups, according to
presence or absence of extrahepatic autoimmune disease
and then to presence or absence of AMA positivity, in or-
der to analyze statistically significant differences in terms
of clinical presentation and laboratory tests. In addition,
they were divided in three age groups (< 45 years, 45 - 65
years, > 65 years) in order to perform a similar compari-
son.
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Typing of HLA class II DRB1 alleles, performed in 31 PBC
patients, was compared with that of 237 healthy control
subjects. The relative risk was calculated using Fischer’s
test and Bonferroni correction method. After IL28B geno-
typing for rs12979860 and rs8099917 polymorphisms (n =
32), clinical, laboratory and histological features as well as
disease progression of CC vs. non-CC rs12979860 and TT vs.
non-TT rs8099917 patients were compared.
A Cox regression analysis was performed to identify
the presence of independent predictors of clinical progres-
sion. A multivariate analysis including all the significant
baseline variables (P < 0.05) was also conducted using a bi-
nary logistic regression.
All statistical analysis were performed using a SPSS v.
20.0 for Macintosh (SPSS Inc., Chicago, USA).
4. Results
4.1. Baseline Features
Baseline demographic, laboratory, clinic, histologic
and genetic characteristics of 81 patients with PBC are sum-
marized in Table 1. The mean age was 53.2 years (range 31
- 84), with a strong predominance of female sex (96.3%).
Fourteen patients (17.3%) were diagnosed over the age of 65
years. Median gamma-glutamyl transpeptidase (GGT) val-
ues were five times the upper limit of normal (X u.l.n.) and
those of alkaline phosphatase (AP) 3 X u.l.n. Median val-
ues of aspartate and alanine transferase (AST and ALT) were
slightly higher than normal, even if 24 patients (24.6%) had
values more than 2 X u.l.n. The median value of total choles-
terol was 213 mg/dL with an interquartile range between
199 and 244 mg/dL.
Seventy-one out of eighty-one (87.7%) patients showed
AMA positivity with titer≥ 1:40, while ten were AMA nega-
tive. Amongst these, seven (12.3%) showed antinuclear au-
toantibodies (ANA) positivity with titer ≥ 1:80, two ANA
and smooth muscle antibodies (SMA) positivity and one
SMA positivity only. Comparing PBC AMA-positive and PBC
AMA-negative cases, no significant differences regarding
age and laboratory features at onset were found (data not
shown).
Liver biopsy was performed in 77 out of 81 patients.
Amongst these, 71.4% presented an early histological stage
(Scheuer stage I and II) and 28.6% an advanced stage
(Scheuer stage III and IV).
Two thirds of patients were symptomatic at the time
of diagnosis. Most common symptoms were: pruritus
(51.6%), asthenia (16.1%), xerostomia (16.1%), xerophthalmia
(13.6%), arthralgia (3.7%) and right upper abdominal quad-
rant discomfort (3.7%). Thirty-three (40.7%) patients had
extrahepatic autoimmune diseases associated with PBC.
Table 1. Baseline Demographic, Laboratory, Clinic, Histologic Characteristics of 81
Patients with Primary Biliary Cirrhosisa
Characteristics
Age - years, mean± SD (range) 53.2± 12.2 (31 - 84)
Female gender 78 (96.3)
Antimitocondrial Antibodies (AMA) 71 (87.7)
Antinuclear Antibodies (ANA) 31 (38.3)
Smooth Muscle Antibodies (SMA) 6 (7.4)
γ-Glutamyl Transpeptidase (IU/L), median (I.Q.I.) 164 (83 - 322)
Alkaline Phosphatase (IU/L), median (I.Q.I.) 297 (160 - 425)
Aspartate Aminotransferase (IU/L), median (I.Q.I.) 41 (33 - 70)
Alanine Aminotransferase (IU/L), median (I.Q.I.) 48 (34 - 80)
Total Bilirubin (mg/dL), mean± SD 0.76± 0.7
Platelets (x103 /mmc), mean± SD 242± 84.5
Symptomatics 54 (66.7)
Pruritus 42 (51.6)
Fatigue 13 (16.1)
Xerostomia 13 (16.1)
Xerophtalmia 11 (13.6)
Arthralgias 3 (3.7)
Right upper abdominal quadrant discomfort 3 (3.7)
Extrahepatic autoimmune diseases 33 (40.7)
Sjogren’s Syndrome 22 (27.2)
Autoimmune Thyroiditis 7 (8.6)
Rheumatoid arthritis 3 (3.7)
Seronegative Spondyloarthritis 1 (1.2)
Liver Histology (n = 77)
Stage I 15 (19.5)
Stage II 40 (51.9)
Early (I - II) 55 (71.4)
Stage III 13 (16.9)
Stage IV 9 (11.7)
Advanced (III - IV) 22 (28.6)
aValues are expressed as No. (%) unless otherwise indicated.
Amongst these, the most frequent one was Sjogren’s syn-
drome (27.2%). No significant differences were found on
the clinical presentation and laboratory tests between pa-
tients with and without extrahepatic autoimmune dis-
eases.
The comparison of the three groups of patients that
were distributed according to age (< 45 years, n = 24, 45-
65 years, n = 43, > 65 years, n = 14) showed that subjects
younger than 45 years had higher ALT (P = 0.038) and AP
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levels (P = 0.047) than older cases (Table 2).
4.2. Subgroup Analysis for IL28B Polymorphisms
Aiming to better define the genetic profile of our
Mediterranean PBC cohort and considering the pivotal role
of IL28B polymorphisms in modulating inflammatory re-
sponse and progression of liver disease in different clinical
settings, we decided to test a small number of PBC patients
for IL28B polymorphisms.
Baseline demographic, clinic, laboratory and histologi-
cal features as well as IL28B rs12979860 and rs8099917 poly-
morphisms frequency of 32 PBC patients are shown in Ta-
ble 3. In comparison to non-CC rs12979860 (n = 16), CC
rs12979860 genotype (n = 16) was associated with early his-
tological stage (93.8% vs. 62.5%, P = 0.03) and higher mean
ALT levels (71± 64 vs. 50± 25, P = 0.05) at univariate analy-
sis. No statistically significant differences were found com-
paring non-TT rs8099917 patients with TT rs8099917 ones.
4.3. Subgroup Analysis for HLA Class II Typing
HLA-DRB1 allele frequencies of 31 PBC patients are re-
ported in Table 4. Compared to healthy controls (n = 237),
we found a higher frequency of HLA-DRB1 * 07 (39.2% vs.
11.4%, RR 5.03) and HLA-DRB1 * 08 (10.7% vs. 0, RR n.c.).
4.4. Analysis of Follow-up
Amongst the 73 patients in follow-up (mean duration
61 months), three died (two because of cardiovascular dis-
ease and one because of end-stage liver disease) and one
underwent liver transplantation. Overall, 16 (21.9%) pa-
tients had progression of a disease (Table 5).
The rate of progression of disease was equal amongst
patients with AMA positivity or AMA negativity. Fur-
thermore, 81.3% of patients with disease progression had
medium/intense itching during follow-up and amongst all
patients with medium or intense itching, 48.1% had dis-
ease progression as compared to 6.5% without pruritus.
Five years after diagnosis, 13% of patients with initial his-
tological stage and 49% of patients with advanced histo-
logical stage showed sonographic signs of portal hyper-
tension, whereas 8% of patients with initial histological
stage and 27% with advanced histological stage developed
esophageal varices (Figure 2). Notably, no patient devel-
oped hepatocellular carcinoma.
The only independent risk factors associated with dis-
ease progression for the multivariate analysis was, the
presence of extrahepatic autoimmune disease (P = 0.049,
RR 2.96), pruritus for more than one year (P = 0.008, RR
3.84) and advanced histological stage (P < 0.001, RR 8.31)
(Table 6).
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Figure 2. Event-Free Survival (Portal Hypertension) in PBC Patients with Early Stage
(Solid Line) and Advanced Stage (Broken Line); P = 0.026 by Log-Rank Test
5. Discussion
Primary biliary cirrhosis, as well as other autoimmune
diseases are more common in Caucasian populations. Nev-
ertheless, few European studies exist on epidemiology and
disease course of PBC and most of them are derived from
Northern European cohorts (3). In addition, natural his-
tory of PBC is incompletely characterized in patients of the
Mediterranean area whose genetic background and risk
factors might differ from those of Northern Europeans.
Our patients showed demographic, clinical and bio-
chemical features at onset, which was very similar to those
described in other population-based cohorts. In particular,
patients with AMA-negative PBC have a comparable presen-
tation and progression of the disease compared to AMA-
positive subjects, as already stated by several evidences (1).
A more severe cytolytic pattern was observed at onset in
younger patients compared with older ones, a trend that
was already emphasized by Muratori et al. (31). Interest-
ingly, the most common symptom in our cohort was pru-
ritus, which was complained in a sporadic or constant way
in about half of the patients at diagnosis, while fatigue was
less reported (16% of patients). These two symptoms have
been related to an impairment of the quality of life with po-
tential serious repercussions (32, 33). In a study by Prince et
al. (34), the prevalence of fatigue at diagnosis was similar
to that reported in our cohort (21%) but itching was present
at diagnosis in only 18.9% of patients, a smaller proportion
compared with our findings.
The rate of progression of PBC is extremely variable (1).
In our cohort, presence of pruritus for more than one year,
an advanced histological stage at diagnosis and the pres-
ence of extrahepatic autoimmune disease were found to be
independently associated with disease progression. With
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Table 2. Comparison Between Groups of Age (< 45 Years, n = 24; 45 - 65 Years, n = 43; > 65 years, n = 14) on Laboratory Characteristics at Onset: Univariate Analysis
Variable < 45 years, (n = 24) 45 - 65 years, (n = 43) > 65 years, (n = 14) P
ALT (IU/L), median (I.Q.I.) 62 (47 - 99) 44 (32 - 71) 33 (22 - 71)
0.038
ALT (x u.l.n.), median (range) 2xN (1.1 - 8.4) 1.5xN (0.3 - 8.5) 1xN (0.71 - 4.6)
AP (IU/L), median (I.Q.I.) 411 (247 - 563) 296 (115 - 408) 165 (93 - 271)
0.047
AP (x u.l.n.), median (range) 4xN (1.4 - 21) 3xN (0.5 - 9) 1.5xN (0.4 - 4.4)
Abbreviations: ALT, Alanine aminotransferase; AP, Alkaline phosphatase.
Table 3. Univariate Analysis on Demographic, Laboratory, Clinical and Histological Characteristics at Onset Between PBC Patients With CC rs12979860 (n = 16) vs. non-CC
rs12979860 (n = 16) Interleukin-28B Polymorphism
Variable CC rs12979860 (n = 16) Non-CC rs12979860 (n = 16) P
Age - years, mean± SD 54± 10 52± 14 n.s.
Total Bilirubin (mg/dL), mean± SD 0.6± 0.24 0.53± 0.29 n.s.
Alanine aminotransferase (IU/L), mean± SD 71± 64 50± 25 0.05
γ-Glutamyl Transpeptidase (IU/L), mean± SD 188± 125 199± 173 n.s.
Alkaline Phosphatase (IU/L), mean± SD 281± 222 295± 171 n.s.
Platelets (x103 /mmc), mean± SD 266± 64 233± 95 n.s.
Symptomatics, No. (%) 6 (37.5) 10 (62.5) n.s
Extrahepatic autoimmune diseases, No. (%) 8 (50) 8 (50) n.s
Liver Histology, No. (%) 0.03
Early (I - II) 15 (93.8) 10 (62.5)
Advanced (III - IV) 1 (6.7) 6 (37.5)
Table 4. Typing of HLA Class II Alleles of Major Histocompatibility Complex (MHC) in PBC Patients Compared to a Control Group of Healthy Subjectsa
DRB1 Alleles PBC (n = 28) Controls (n = 237) R. R. P P*
HLA DRB1*07 11 (39.2) 27 (11.4) 5.03 0.00007 0.0008
HLA DRB1*08 3 (10.7) 0 n.s. 0.00004 0.0005
HLA DRB1*14 5 (17.8) 16 (6.7) 3.0 0.02 n.s.
HLA DRB1*11 4 (14.2) 87 (36.7) 0.28 0.04 n.s.
HLA DRB1*13 6 (21.4) 24 (10.1) n.s. n.s.
HLA DRB1*15 2 (7.1) 63 (26.5) 0.21 0.02 n.s.
aValues are expressed as No. (%).
regards to the first, several authors already reported that
symptomatic patients at diagnosis have a shorter survival
rate compared with asymptomatic subjects (35, 36). It is in-
teresting that among all the symptoms only itching was as-
sociated with progression of the disease. The presence of
an advanced histological stage is recognizably associated
with a greater rate of progression, due to the fact that it
is representative of a disease, which was already advanced
at diagnosis in most of the cases. Lastly, the association of
other autoimmune diseases, with a less favourable progno-
sis, had already been suggested by several lines of evidence
(36). Nonetheless, the association of PBC with other au-
toimmune diseases further confirms the immune patho-
genesis of the disease. In our cohort, 33 (40.7%) out of 81
patients showed an association with extrahepatic autoim-
mune diseases. Amongst these, the most frequent one was
Sjogren’s syndrome (27.2%). This finding confirms its high
prevalence in patients with PBC, as reported by recent stud-
6 Hepat Mon. 2016; 16(11):e31681.
Almasio PL et al.
Table 5. Events Leading to Disease Progression in 16 out of 73 PBC Patient (Mean
Follow-Up 61 Months)a
Event (Disease Progression: n = 16) N = 73
US signs of portal hypertension 20 (27.4)
Esophageal varices 11 (15.1)
Ascites 3 (4.1)
Hepatic encephalopathy 2 (2.7)
Jaundice (bilirubin >5 mg/dL) 2 (2.7)
Liver transplantation 1 (1.4)
Death 3 (4.1)
Hepatocellular carcinoma 0
aValues are expressed as No. (%).
ies (37, 38).
Interestingly, the median value of the total cholesterol
was quite high in comparison to that of the healthy popu-
lation. A recent systematic review (39) showed that choles-
terol levels are increased in about 50% of patients with
PBC. Essentially, 75% of the patients in our series had a to-
tal cholesterol value greater than the normal values (> 200
mg/dL). Even if the risk of mortality from cardiovascular
disease is not increased in patients with PBC, despite the
presence of hypercholesterolemia (40), we reported two
deaths for cardiovascular events during follow-up.
Typing of HLA class II alleles of MHC in a subgroup of
patients (n = 31) and its comparison with a control group
of healthy subjects (n = 237) showed a higher frequency
of HLA-DRB1 * 07 and HLA-DRB1 * 08 in PBC. In contrast to
other series from Northern Europe (5), we also reported a
higher prevalence of a DRB1 * 08 allele of HLA class II, re-
spect to DRB1 * 07. This difference may reflect a different ge-
netic background of patients from the Mediterranean area
as compared to those of Northern Europe.
One of the most interesting findings arising from our
cohort lies in the statistically significant association be-
tween CC IL28B rs12979860 genotype, early histological
stage and higher mean ALT values. To our knowledge, this
is the first study assessing the potential association be-
tween IL28B polymorphisms and the severity of liver dam-
age in PBC patients. Our original result is consistent with
the identification of an independent association between
the presence of IL28B CC homozygosis, the genotype as-
sociated with a good response to antiviral therapy in pa-
tients with chronic hepatitis C (41), and the severity of in-
flammation at early stages in patients with PBC. In this line,
growing evidences demonstrated that IL28B rs12979860
polymorphism strongly affects the histological severity of
chronic liver diseases, in terms of both necroinflammation
and fibrosis progression, independently of the underlying
etiology (24, 41-43). By contrast, we did not find any asso-
ciation with IL28B rs12979917 polymorphism. However, it
should be noted that our data is not consistent enough to
evaluate whether patients with PBC have a higher preva-
lence of IL28B rs12979860 CC genotype compared to the
Mediterranean general population, due to the lack of data
in this setting. Of note, we can only observe that the fre-
quency (about 50%) of IL28B rs12979860 CC genotype in our
PBC cohort is higher compared with that reported (about
30%) in Sicilian patients with chronic hepatitis C (44) and
similar to that observed (46%) in a homogeneous cohort of
301 Sicilian patients with thalassemia major (45).
Evidently, the main and biggest limitation of our study
lies in the small simple size of our cohort and the fact that
the genetic analysis was performed on a fraction of pa-
tients only. In addition, data regarding the progression
of the disease is mainly limited to development of por-
tal hypertension, an aspect likely due to the small num-
ber of reported events. However, although all of the above
data needs further validation in larger studies, they might
identify a subgroup of PBC patients at a higher risk of dis-
ease severity and progression deserving a more rigorous
follow-up. Furthermore, these high-risk patients may be
the ideal candidates who could benefit from possible fu-
ture experimental treatments of chronic liver diseases fo-
cused on liver regeneration, including the use of endoge-
nous hepatocytes, fetal hepatic stem cells, bone marrow-
derived stem cells and embryonic stem cells and induced
pluripotent stem cells (46).
In conclusion, our prospective cohort study provides
further insights in the natural history and overall ge-
netic background of Mediterranean patients with PBC.
At disease onset, a more severe biochemical activity was
observed in younger patients, while the presence of
rs12979860 CC genotype was associated with a milder his-
tological stage. Persistence of pruritus and presence of ex-
trahepatic autoimmune liver disease were significantly as-
sociated with a poorer prognosis. Taken altogether, these
findings might be useful to identify subgroups of PBC pa-
tients at different risks of disease severity and progression.
However, larger studies are needed in this setting to elab-
orate novel follow-up protocols or treatment strategies for
such patients.
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